Artificial intelligence powered medtech diagnostic dev MaxQ AI has pulled the plug on an upcoming initial public offering looking to raise approximately $8.1 million, according to a recently posted SEC filing.
MaxQ developed and produces the Accipio Insight intracranial hemorrhage platform intended to support acute care physicians by identifying patients with suspected intracranial hemorrhage using non-contrast head computed tomography imaging, according to the company’s website.
The Israel-based company had not yet revealed how many shares it was looking to float in the IPO, but said that it planned to list on the Nasdaq Capital Market under the ticker symbol “MQAI,” according to an SEC filing.
In a recently posted filing, the AI-powered medtech dev firm said that it was seeking the immediate withdrawal of its previous registration statement, which it said it originally filed last August.
MaxQ AI has not yet officially commented on why it withdrew its IPO registration or if it has plans to fully cancel or delay the offering.
Last November, Samsung Electronics (LON:BC94) subsidiary NeuroLogica said that it inked a distribution deal with MaxQ AI to integrate its artificial intelligence software with NeuroLogica’s medical imaging tech in the U.S. and EU’s acute care marketplace.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!